[Disclosure] Celltrion (068270) Secures FDA Approval to Modify Phase 3 Clinical Trial Plan for ‘CT-P55’ (Cosentyx Biosimilar)

Fact Source: Financial Supervisory Service DART / 2026-05-12

Disclosure Type: Major Management Event Related to Investment Judgement

💡 3-Second Summary

Following the expiration of the standard 60-day review period, Celltrion has formally secured administrative approval from the U.S. FDA for its protocol modification request for the global Phase 3 trial of CT-P55, its biosimilar candidate for the autoimmune therapy ‘Cosentyx.’

📊 1. [Summary of Key Disclosure Content and Figures]

• Clinical Phase & Target Indication: Global Phase 3 Clinical Trial / Plaque Psoriasis
• Submission & Approval Dates:
  • Modification Submission Date: March 12, 2026 (local time)
  • Effective Approval Date (Confirmation Date): May 12, 2026 (local time)
• Regulatory Authority: U.S. Food and Drug Administration (FDA)
• Clinical Trial Registration Number: EU CT number 2024-513348-27-00
• Trial Size & Methods:
  • Number of Subjects: 153 patients in total
  • Trial Duration: 56 weeks
  • Trial Design: Randomized, active-controlled, double-blind, Phase 3 trial
• Approval Verification Basis: The U.S. FDA does not issue physical notifications for IND modification approvals. Thus, the effective approval date was indexed as May 12, 2026, marking 60 days post-submission pursuant to the review deadlines outlined in the FDA’s Manual of Policies and Procedures (MAPP) 6030.9.
• Future Operations: The company aims to compare and evaluate the efficacy and safety of CT-P55 against the reference drug Cosentyx to establish bio-similarity.

📈 2. [Professional Insight: What This Disclosure Means for Investors]

• Finalization of Phase 3 Framework Supporting Development Momentum: This approval completes the protocol adjustments for the Phase 3 trial program that originally secured FDA validation back in August 2024. Establishing a finalized 153-subject cohort protocol under current regulatory guidelines eliminates administrative overhang, allowing the active Phase 3 program to proceed with enhanced operational focus.
• Mitigation of Regulatory Pipeline Friction: Passing the FDA’s strict MAPP 6030.9 60-day review threshold without objections or requests for additional data represents a solid regulatory clearance. Resolving this technical administrative loop reduces the risk of unexpected operational delay, allowing clinical sites to move forward within the target execution timeline.
• Evaluating Biotech R&D Risk Thresholds: While entering the clinical execution phase for a major biologics play targeting the massive Cosentyx market is positive, late-stage drug development remains fundamentally high-risk. Statistically, the average success rate for a clinical candidate to secure final marketing authorization is restricted to roughly 10%. Investors should keep in mind that unexpected safety signals or efficacy gaps during the 56-week program could lead to delays or shifts in commercialization plans.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has cleared a key administrative gateway for its Cosentyx biosimilar candidate, CT-P55, in the United States. Following the standard 60-day review framework under FDA guidelines, the company’s modified Phase 3 protocol has become officially active. This is a technical clinical update with no near-term capital-raising dilution or market supply-side friction. It locks in the parameters of a 56-week comparative trial across a 153-patient plaque psoriasis cohort. Although investors must always evaluate clinical pipelines against the historical 10% average regulatory approval rate, clearing this administrative threshold allows Celltrion’s clinical infrastructure to scale up patient enrollment under a validated protocol. Global trading desks should treat this as a solid, steady operational step reinforcing the company’s long-term biosimilar expansion pipeline.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.